Amicus Therapeutics
FOLD

$10.18

0.78%

Market Cap: 3.02B

About: Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Employees: 517

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 7 analysts

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

115% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 20

21% more call options, than puts

Call options by funds: $6.36M | Put options by funds: $5.25M

18% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 76

10% more funds holding

Funds holding: 222 [Q4 2023] → 245 (+23) [Q1 2024]

1.28% less ownership

Funds ownership: 108.65% [Q4 2023] → 107.38% (-1.28%) [Q1 2024]

17% less capital invested

Capital invested by funds: $4.52B [Q4 2023] → $3.74B (-$784M) [Q1 2024]

25% less funds holding in top 10

Funds holding in top 10: 8 [Q4 2023] → 6 (-2) [Q1 2024]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$13

28%

upside

Avg. target

$17.57

73%

upside

High target

$22

116%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Wells Fargo	77%upside $18	Overweight Initiated	30 May 2024
Guggenheim Debjit Chattopadhyay	28%upside $13	Buy Upgraded	14 May 2024
UBS Karl Chalabala	87%upside $19	Buy Maintained	10 May 2024
Morgan Stanley Jeffrey Hung	87%upside $19	Overweight Maintained	10 May 2024
B of A Securities Tazeen Ahmad	28%upside $13	Buy Maintained	10 May 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about FOLD published over the past 30 days

In NCLA Amicus Win, Fifth Circuit Rules Against FCC's Unlawful Control of Universal Service Fund

Washington, D.C., July 24, 2024 (GLOBE NEWSWIRE) -- Today, the en banc U.S. Court of Appeals for the Fifth Circuit ruled in Consumers' Research v.

In NCLA Amicus Win, Fifth Circuit Rules Against FCC's Unlawful Control of Universal Service Fund

In NCLA Amicus Win, Supreme Court Upholds Small Business's Right to Judicial Review

Corner Post, Inc. v. Board of Governors of the Federal Reserve System Corner Post, Inc. v. Board of Governors of the Federal Reserve System

In NCLA Amicus Win, Supreme Court Upholds Small Business's Right to Judicial Review

In NCLA Amicus Win, Supreme Court Restores Americans' Rights to Trial by Jury

Securities and Exchange Commission v. George R. Jarkesy, Jr. and Patriot28, L.L.C. Securities and Exchange Commission v. George R. Jarkesy, Jr. and Patriot28, L.L.C.

In NCLA Amicus Win, Supreme Court Restores Americans' Rights to Trial by Jury

In NCLA Amicus Win, Fifth Circuit Upholds Permanent Block on Treasury's Illegal State Tax Cut Ban

State of Texas; State of Mississippi; State of Louisiana v. Janet Yellen, Richard K. Delmar, U.S. Department of the Treasury, United States of America State of Texas; State of Mississippi; State of Louisiana v. Janet Yellen, Richard K. Delmar, U.S. Department of the Treasury, United States of America

In NCLA Amicus Win, Fifth Circuit Upholds Permanent Block on Treasury's Illegal State Tax Cut Ban

In NCLA Amicus Win, Supreme Court Overturns NLRB-Specific Preliminary Injunction Standard

Starbucks Corporation v. M. Kathleen McKinney, Regional Director of Region 15 of the NLRB Starbucks Corporation v. M. Kathleen McKinney, Regional Director of Region 15 of the NLRB

In NCLA Amicus Win, Supreme Court Overturns NLRB-Specific Preliminary Injunction Standard

In NCLA Amicus Win, Tenth Circuit Clears Path to Toppling Intrusive Dog Kennel Inspection Regime

Scott Johnson, Harlene Hoyt, Covey Find Kennel, LLC v. Justin Smith, D.V.M., in his official capacity as Animal Health Commissioner at the Kansas Department of Agriculture Scott Johnson, Harlene Hoyt, Covey Find Kennel, LLC v. Justin Smith, D.V.M., in his official capacity as Animal Health Commissioner at the Kansas Department of Agriculture

In NCLA Amicus Win, Tenth Circuit Clears Path to Toppling Intrusive Dog Kennel Inspection Regime

In NCLA Amicus Win, Fifth Circuit Topples SEC's Unlawful Effort to Regulate Private Funds

National Association of Private Fund Managers, et al. v. Securities and Exchange Commission National Association of Private Fund Managers, et al. v. Securities and Exchange Commission

In NCLA Amicus Win, Fifth Circuit Topples SEC's Unlawful Effort to Regulate Private Funds

Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T.

Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

3 Biotech Names Under $10 I Own

Today, we take a look at three promising biotech names that currently trade under $10 a share. Two of these are quickly moving towards profitability, and the other is cash rich and has several partnerships with large pharma companies. We profile all three of these names with favorable risk/reward profiles in the paragraphs below.

3 Biotech Names Under $10 I Own

Amicus Therapeutics: Too Cheap At Under $10 A Share

Amicus Therapeutics has recently seen its shares slide under $10, despite strong revenue growth. The company's products, Galafold and Pombiliti + Opfolda, have significant sales potential and are seeing good sales traction. Analyst firms are also largely positive on the company's prospects.

Amicus Therapeutics: Too Cheap At Under $10 A Share

See News Rankings